Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

AASLD/IDSA HCV Guidance Panel

doi:10.1002/hep.27950

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

MeSH — NLM indexing Adult Antiviral Agents / administration & dosage Disease Progression Disease Transmission, Infectious / prevention & control Evidence-Based Medicine Female Hepacivirus / drug effects Hepacivirus / isolation & purification Hepatitis C / diagnosis Hepatitis C / drug therapy Hepatitis C / epidemiology Hepatitis C, Chronic / diagnosis Hepatitis C, Chronic / drug therapy Hepatitis C, Chronic / epidemiology Humans Liver Neoplasms / prevention & control Liver Neoplasms / virology Male Mandatory Testing / standards Patient Education as Topic Practice Guidelines as Topic Risk Assessment Societies, Medical

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Key publication Fibrotest Actitest Guideline Independent Group United States

Authors (1)

AASLD/IDSA HCV Guidance Panel

Citation

AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54. doi:10.1002/hep.27950.

Identifiers

DOI: 10.1002/hep.27950
PMID: 26111063

Tests

Liver diseases

Liver injuries

Comparisons

Subjects

Region

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.